Novo Nordisk shared a new analysis of its next-generation experimental drug, with results focused on women with obesity or overweight.
Recap by typeshit. Full story at Reuters on MSN.
Endpoints News
Endpoints reports Eli Lilly is building a case for its triple agonist beyond obesity, where a launch is expected next year, with sleep apnea next in line.
Observational data link GLP-1 drugs to fewer cases of some cancers, but trials have yet to show they prevent cancer or help survival after a diagnosis.
BusinessWorld Online covers a Lilly weight loss drug still in clinical trials. Few details were given beyond the headline.
A short social post says drugs like Ozempic may lower heart attack and stroke risk, possibly beyond what weight loss alone explains.
Labiotech walks through Novo Nordisk's 2026 pipeline and the new target it has set for risk-adjusted sales from drugs still in development.
The obesity medicine specialist told a Fall Clinical 2026 panel that sleep apnea, MASH and heart coverage can open GLP-1 access, and that retatrutide could reach market next year.
Loading…